CONMED Corporation (CNMD)

Several events have impacted CONMED's stock price in the past six months. CONMED reported Q3 2025 sales with a year-over-year increase and announced a share repurchase program while suspending its quarterly cash dividend. The company announced its intent to exit its gastroenterology product lines. CONMED reported Q4 and full-year 2025 financial results and issued 2026 guidance. Todd Garner stepped down as CFO. CONMED announced Q1 2026 financial results and raised its outlook for full-year 2026 organic revenue growth. CONMED's stock has experienced a decline, and analysts have given it a consensus rating of "Reduce" or "Hold".

The medical device industry experiences seasonal variations in demand. CONMED's "Days Inventory" metric is compared year-over-year due to the seasonal nature of the sector. The company's Q1 2026 earnings call indicated variability in demand for certain offerings. The company's strategic focus aims to leverage consistent demand drivers.

CONMED Corporation is a global medical technology company focused on surgical and patient care products. It operates in the Healthcare sector, specifically in Medical Technology, Surgical Devices, and Health Care Equipment. The company's core business is structured around Orthopedic Surgery and General Surgery segments, offering a range of products including arthroscopy products, powered surgical instruments, electrosurgical products, and advanced energy solutions.

CONMED has a significant global presence, operating in over 100 countries. It serves hospitals, surgical centers, and healthcare providers through direct sales and distributor partnerships. Its international footprint spans North America, Europe, Latin America, Asia Pacific, and various emerging markets, with the majority of revenue generated from the United States. The company maintains sales subsidiaries and branches in numerous countries.

CONMED's products are marketed under recognized brand names known for quality and service. No specific events explicitly affecting CONMED's brand reputation have been prominently reported in the past year. In 2024, the company faced supply chain challenges that led to lost market share in its orthopedic segment, which could have indirectly impacted its reputation for product availability.

CONMED Corporation's ownership is primarily dominated by institutional investors and mutual funds, including BlackRock, Inc., Vanguard Group Inc., Earnest Partners Llc, Fuller & Thaler Asset Management, Inc., and State Street Corp. Individual insider ownership is modest.